What is the official website of Novartis Slovakia ?

The official website of Novartis Slovakia is https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin.

What is Novartis Slovakia's cybersecurity risk score?

Novartis Slovakia has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Slovakia experienced?

According to Rankiteo, Novartis Slovakia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Slovakia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Slovakia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Slovakia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Slovakia is not certified under SOC 2 Type 1.

Does Novartis Slovakia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Slovakia does not hold a SOC 2 Type 2 certification.

Does Novartis Slovakia comply with GDPR ?

According to Rankiteo, Novartis Slovakia is not listed as GDPR compliant.

Does Novartis Slovakia have PCI DSS certification ?

According to Rankiteo, Novartis Slovakia does not currently maintain PCI DSS compliance.

Does Novartis Slovakia comply with HIPAA ?

According to Rankiteo, Novartis Slovakia is not compliant with HIPAA regulations.

Does Novartis Slovakia have ISO 27001 certification ?

According to Rankiteo,Novartis Slovakia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Slovakia operate in ?

Novartis Slovakia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Slovakia have ?

Novartis Slovakia employs approximately 59 people worldwide.

Does Novartis Slovakia own any subsidiaries ?

Novartis Slovakia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Slovakia have ?

Novartis Slovakia's official LinkedIn profile has approximately 3,510 followers.

What is the NAICS classification code for Novartis Slovakia ?

Novartis Slovakia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Slovakia have a Crunchbase profile ?

No, Novartis Slovakia does not have a profile on Crunchbase.

Does Novartis Slovakia have a LinkedIn profile ?

Yes, Novartis Slovakia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-slovakia.

How many cybersecurity incidents has Novartis Slovakia experienced ?

As of August 18, 2026, Rankiteo reports that Novartis Slovakia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Slovakia have ?

Novartis Slovakia has an estimated 5,729 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Slovakia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Slovakia

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Slovakia Vendor Cyber Rating & Cyber Score

https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin

Add Your Compliance Badge

Sme globálnou farmaceutickou spoločnosťou, ktorá pôsobí v 140 krajinách sveta a zamestnáva približne 125-tisíc ľudí. V našej snahe nájsť nové lieky sa nachádzame medzi poprednými svetovými spoločnosťami, ktoré investujú do výskumu a vývoja. Naším poslaním je objavovať nové riešenia, ktoré zlepšujú a predlžujú život pacientov. Naše produkty užíva celosvetovo miliarda ľudí a hľadáme inovatívne spôsoby, ako rozšíriť prístup k našej liečbe. Na Slovensku prinášame liečbu v rámci kardiológie, imunológie, dermatológie, neurológie, oftalmológie, respirológie, onkológie a génovej terapie. We are leading a global pharmaceutical company, employing more than 125 000 people in 140 countries all around the world. In our quest to find new medicines, we

Novartis Slovakia A.I CyberSecurity Scoring

Scoring History

Novartis Slovakia

Novartis Slovakia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Slovakia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Slovakia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Slovakia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incident Types Novartis Slovakia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incident History - Novartis Slovakia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Slovakia Subsidiaries

Novartis Slovakia

Pharmaceutical Manufacturing

Website: https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin

Company Size: 59

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Loading…

Novartis Slovakia Similar Companies

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

Novartis Slovakia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-9693

SUMMARY

Mattermost versions 10.11.x <= 10.11.20, 11.7.x <= 11.7.5 Mattermost fails to remove thread membership records when a user is removed from or leaves a team, which allows a previously removed user who is later re-invited to the team to view private channel thread root post content and metadata via the team threads API.. Mattermost Advisory ID: MMSA-2026-00682

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 3.5)

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.1

REFERENCES

https://mattermost.com/security-updates

CVE-2026-75587

SUMMARY

Mattermost Desktop App versions <=6.2 6.2.2.0 fail to redact the pre-auth secret when generating a diagnostics report, which allows a local attacker with access to a user's diagnostics report or log files to obtain the plaintext pre-auth secret configured for a connected server via inspecting the Server Connectivity (Step-3) diagnostics output. Mattermost Advisory ID: MMSA-2026-00716

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 3.6)

cvss3

Base Score: 3.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:C/C:L/I:N/A:N

Impact Score

1.4

Exploitability

1.8

REFERENCES

https://mattermost.com/security-updates

CVE-2026-75078

SUMMARY

A security flaw has been discovered in SourceCodester Class and Exam Timetabling System 1.0. This affects an unknown part of the file /BSHRM1.php. Performing a manipulation of the argument course results in cross site scripting. Remote exploitation of the attack is possible. The exploit has been released to the public and may be used for attacks.

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-67961

SUMMARY

An issue in O2OA v.10.0.2 allows a local attacker to execute arbitrary code via the the sandbox mechanism of the Invoke script execution.

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67919

SUMMARY

An issue in Halo 2.25.4 allows a remote attacker to execute arbitrary code via the PluginEndpoint.java, installFromUri method, and DefaultPluginApplicationContextFactory components

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…